Great Point Partners’s TherapeuticsMD TXMD Stock Holding History

Great Point Partners’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-69,205	Closed	-$24.9M	–	43
2017 Q1	$24.9M	Buy	69,205 +3,685	+6%	+$1.14M	4.95%	8
2016 Q4	$18.9M	Buy	+65,520	New	+$20.3M	3.88%	13
2013 Q4	–	Sell	-8,333	Closed	-$1.22M	–	34
2013 Q3	$1.22M	Buy	+8,333	New	+$1.01M	0.85%	24

Other funds holding TXMD

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return

Great Point Partners's TXMD Position: Q2 2017 in Review

Great Point Partners sold out of TherapeuticsMD (TXMD) in Q2 2017, closing a stake of 69,205 shares — an estimated $24.9M sold.

Great Point Partners first reported a position in TXMD in Q3 2013 and held it in 3 quarters. The position peaked at $24.9M in Q1 2017. 117 funds tracked by Wall St. Rank hold TXMD as of Q2 2017.

Great Point Partners reported no remaining TherapeuticsMD position as of Q2 2017 after selling out during the quarter.
Great Point Partners sold 69,205 TherapeuticsMD shares in Q2 2017, an estimated $24.9M.
Great Point Partners first reported a position in TherapeuticsMD in Q3 2013 and held it in 3 quarters.
Great Point Partners's TherapeuticsMD position peaked at $24.9M in Q1 2017.
117 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2017.

Based on Great Point Partners's 13F filing for Q2 2017, filed 14 Aug 2017.